Page 149 - NobleCon19revC2_Neat

PDS Biotechnology Corporation

SELECTED FINANCIAL ITEMS PDSB

(in millions of USD)
CQ4 '22 CQ1 '23 CQ2 '23 CQ3 '23 LTM
Income Statement Key Items
Total Revenue NA NA NA NA 0.00
Gross Profit NA NA NA NA 0.00
Gross Margin NM NM NM NM NM
EBIT (18.82) (9.42) (12.70) (10.52) (51.46)
EBIT Margin NM NM NM NM NM
Net Income to Common Shareholders (19.14) (9.66) (11.53) (10.85) (51.18)
Net Margin NM NM NM NM NM

Balance Sheet Key Items
Total Assets 77.01 68.45 63.75 57.19 57.19
Cash & Short Term Investments 73.82 65.20 60.62 54.25 54.25
% of Assets 96% 95% 95% 95% 95%
Current Assets -Total 76.48 67.97 63.35 56.84 56.84
% of Assets 99% 99% 99% 99% 99%
Total Liabilities 33.01 27.44 31.31 32.70 32.70
% of Assets 43% 40% 49% 57% 57%
Current Liabilities - Total 9.82 4.13 7.90 9.15 9.15
% of Assets 13% 6% 12% 16% 16%
Long Term Debt 23.02 23.14 23.25 23.41 23.41
% of Assets 30% 34% 36% 41% 41%
Total Equity 44.00 41.01 32.44 24.48 24.48
% of Assets 57% 60% 51% 43% 43%

Cash Flow Statement Key Items
Net Cash Flow - Operating Activities (7.53) (13.19) (4.81) (7.18) (32.71)
Net Cash Flow - Investing NA NA NA NA 0.00
Net Cash Flow - Financing 9.71 4.57 0.24 0.80 15.32

Source: Capital IQ

PRICE / VOLUME

Source: Channelchek/QuoteMedia

Noble Capital Markets' Nineteenth Annual Small & Microcap Investor Conference